The US Food and Drug
Administration has approved
Bayer’s Adempas (riociguat) to
treat adults with two forms of
pulmonary hypertension, following
strong support from an FDA expert
panel (PD 08 Aug).
The FDA reviewed Adempas
under its priority review program,
which provides for an expedited
six-month review of drugs that may
offer major advances in treatment.
Adempas is not yet approved by
the TGA for marketing in Australia.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.